Is there a role for steroid pulse therapy in acute exacerbation of interstitial lung disease?

Steroid Pulse Therapy in Acute Exacerbation of ILD

For acute exacerbation of interstitial lung disease (ILD), high-dose corticosteroids are commonly used despite limited evidence of benefit, and recent data suggests pulse-dose steroids offer no survival advantage over conventional doses while potentially increasing harm in critically ill patients.

Evidence-Based Approach to Steroid Use in AE-ILD

For Idiopathic Pulmonary Fibrosis (IPF)

The most recent high-quality evidence shows no benefit from pulse-dose steroids in AE-IPF. A 2025 instrumental variable study of 3,049 patients found pulse-dose methylprednisolone (≥250 mg) showed no significant difference in death/hospice discharge compared to low-dose steroids (risk difference 1.2%, 95% CI -6.0% to 8.5%) 1. More concerning, patients admitted to ICU/intermediate care units who received pulse dosing had a 26.3% increased risk of death/hospice discharge (95% CI 10.1%-42.6%, P interaction = .009) 1.

A 2024 retrospective study of 238 AE-IPF patients confirmed these findings, showing pulse-dose corticosteroids did not reduce mortality at 3 months (aHR 0.84,95% CI 0.45-1.38) or 12 months (aHR 0.96,95% CI 0.60-1.25) 2.

For Non-IPF ILD (Connective Tissue Disease-Associated ILD)

The evidence is more nuanced for autoimmune-related ILD:

• For Sjögren's-associated ILD: The 2021 Chest consensus guidelines recommend moderate-dose oral corticosteroids (not exceeding 60 mg daily prednisone) for symptomatic patients with moderate-severe disease 3. Pulse-dose IV corticosteroids or high-dose oral steroids up to 60 mg daily should be reserved only for rapidly progressive ILD or acute respiratory failure 3.

• For anti-ARS antibody-associated ILD: A 2025 study showed pulse corticosteroid therapy (500-1000 mg methylprednisolone IV for 3 days) achieved similar treatment improvement rates (90.3% vs 77.4%, p=0.301) compared to conventional therapy, but with significantly fewer adverse events (25.8% vs 61.3%, p=0.010) and lower maintenance prednisolone doses at 12 months (3.9 mg vs 6.0 mg) 4.

• For progressive non-IPF ILD: Monthly pulse methylprednisolone (1000 mg daily for 3 consecutive days/month) showed 53% of patients had improved lung function, particularly in fibrotic hypersensitivity pneumonitis 5.

Practical Treatment Algorithm

For AE-IPF:

1. Avoid pulse-dose steroids (≥250 mg methylprednisolone)
2. If steroids are used, employ conventional doses (equivalent to prednisone 40-60 mg daily)
3. Never use pulse-dose steroids in ICU/critically ill patients with AE-IPF due to increased mortality risk
4. Evaluate for lung transplantation early
5. Consider palliative care discussions given poor prognosis

For Autoimmune/CTD-Associated ILD with Acute Exacerbation:

1. First-line: Moderate-dose oral corticosteroids (prednisone ≤60 mg daily) with slow taper over weeks-months 3
2. Reserve pulse-dose IV steroids (500-1000 mg methylprednisolone × 3 days) only for:
   • Rapidly progressive ILD requiring hospitalization
   • Acute respiratory failure
   • Anti-ARS antibody-positive patients (may have better risk-benefit profile) 4
3. Add steroid-sparing agents early (mycophenolate or azathioprine as first-line) 3
4. Assess response within 3-7 days by repeat CT imaging 6
5. If no improvement on CT by day 7, consider rituximab or cyclophosphamide 3

Critical Monitoring Points

Assess treatment response by:

• CT chest at 7 days post-pulse: Improvement in ground-glass opacities predicts better survival 6
• Oxygenation improvement within 3 days: Survivors typically show rapid improvement 7
• If no response to first pulse, second pulse is unlikely to help 7

Common Pitfalls to Avoid

1. Do not use pulse-dose steroids routinely in AE-IPF - no mortality benefit and potential harm in critically ill patients 1, 2
2. Do not continue steroids beyond 5-7 days without reassessment - prolonged courses increase adverse events without proven benefit
3. Do not ignore post-surgical complications - pulse steroids after lung resection may cause bronchopulmonary fistulas 7
4. Do not use steroids as monotherapy - combine with steroid-sparing immunosuppressants early in CTD-ILD 3, 8

Key Adverse Events

Pulse-dose steroids increase risk of:

• Hyperglycemia (more common with IV vs oral) 9
• Hypertension worsening 9
• Bronchopulmonary fistulas post-operatively 7
• Longer hospital stays without clear benefit 9
• Insomnia and restlessness on infusion days 5

Bottom Line

The role of pulse-dose steroids in AE-ILD is limited and context-dependent. For AE-IPF, avoid pulse dosing entirely, especially in critically ill patients. For autoimmune-related ILD, pulse steroids may be considered only in rapidly progressive cases, with anti-ARS antibody-positive patients potentially benefiting most from this approach. In all cases, early addition of steroid-sparing agents and close monitoring for treatment response within the first week are essential.